

# Association of the *PHACTR1/EDN1* Genetic Locus With Spontaneous Coronary Artery Dissection



David Adlam, DPHIL,<sup>a,\*</sup> Timothy M. Olson, MD,<sup>b,\*</sup> Nicolas Combaret, MD,<sup>c</sup> Jason C. Kovacic, MD, PhD,<sup>d</sup> Siiri E. Iismaa, PhD,<sup>e,f</sup> Abteahle Al-Hussaini, MB, BS,<sup>a</sup> Megan M. O'Byrne, MA,<sup>g</sup> Sara Bouajila, MD, MS,<sup>c</sup> Adrien Georges, PhD,<sup>h,i</sup> Ketan Mishra, MBTECH,<sup>e,f</sup> Peter S. Braund, PhD,<sup>a</sup> Valentina d'Escamard, PhD,<sup>d</sup> Siying Huang, PhD,<sup>h,i</sup> Marios Margaritis, MD, DPHIL,<sup>a</sup> Christopher P. Nelson, PhD,<sup>a</sup> Mariza de Andrade, PhD,<sup>g</sup> Daniella Kadian-Dodov, MD,<sup>d</sup> Catherine A. Welch, PhD,<sup>a</sup> Stephani Mazurkiewicz, MSc,<sup>h,i</sup> Xavier Jeunemaitre, MD, PhD,<sup>h,i,j</sup> DISCO Consortium, Claire Mei Yi Wong, MGC,<sup>e,f</sup> Eleni Giannoulatou, DPHIL,<sup>e,f</sup> Michael Sweeting, PhD,<sup>a</sup> David Muller, MD,<sup>e,f</sup> Alice Wood, BSc, MB, BS,<sup>a</sup> Lucy McGrath-Cadell, MB, BS, MPH,<sup>f</sup> Diane Fatkin, MD, PhD,<sup>e,f</sup> Sally L. Dunwoodie, PhD,<sup>e,f</sup> Richard Harvey, PhD,<sup>e,f</sup> Cameron Holloway, MD,<sup>e,f</sup> Jean-Philippe Empana, MD, PhD,<sup>h,i</sup> Xavier Jouven, MD, PhD,<sup>h,i</sup> CARDIoGRAMPlusC4D Study Group, Jeffrey W. Olin, MD,<sup>d</sup> Rajiv Gulati, MD, PhD,<sup>b</sup> Marysia S. Tweet, MD,<sup>b</sup> Sharonne N. Hayes, MD,<sup>b</sup> Nilesh J. Samani, MD,<sup>a</sup> Robert M. Graham, MD,<sup>e,f</sup> Pascal Motreff, MD, PhD,<sup>c</sup> Nabila Bouatia-Naji, PhD,<sup>h,i</sup>

## ABSTRACT

**BACKGROUND** Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndromes (ACS) afflicting predominantly younger to middle-aged women. Observational studies have reported a high prevalence of extracoronary vascular anomalies, especially fibromuscular dysplasia (FMD) and a low prevalence of coincidental cases of atherosclerosis. *PHACTR1/EDN1* is a genetic risk locus for several vascular diseases, including FMD and coronary artery disease, with the putative causal noncoding variant at the rs9349379 locus acting as a potential enhancer for the endothelin-1 (*EDN1*) gene.

**OBJECTIVES** This study sought to test the association between the rs9349379 genotype and SCAD.

**METHODS** Results from case control studies from France, United Kingdom, United States, and Australia were analyzed to test the association with SCAD risk, including age at first event, pregnancy-associated SCAD (P-SCAD), and recurrent SCAD.

**RESULTS** The previously reported risk allele for FMD (rs9349379-A) was associated with a higher risk of SCAD in all studies. In a meta-analysis of 1,055 SCAD patients and 7,190 controls, the odds ratio (OR) was 1.67 (95% confidence interval [CI]: 1.50 to 1.86) per copy of rs9349379-A. In a subset of 491 SCAD patients, the OR estimate was found to be higher for the association with SCAD in patients without FMD (OR: 1.89; 95% CI: 1.53 to 2.33) than in SCAD cases with FMD (OR: 1.60; 95% CI: 1.28 to 1.99). There was no effect of genotype on age at first event, P-SCAD, or recurrence.

**CONCLUSIONS** The first genetic risk factor for SCAD was identified in the largest study conducted to date for this condition. This genetic link may contribute to the clinical overlap between SCAD and FMD.

(J Am Coll Cardiol 2019;73:58-66) © 2019 by the American College of Cardiology Foundation.



Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.

From the <sup>a</sup>Department of Cardiovascular Sciences, Glenfield Hospital, Leicester, and National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom; <sup>b</sup>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; <sup>c</sup>Department of Cardiology, University Hospital of Clermont-Ferrand, Auvergne University, Clermont-Ferrand, France; <sup>d</sup>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine, Marie-Josée and Henry R. Kravis Cardiovascular Health Center at Mount Sinai, New York, New York; <sup>e</sup>Molecular Cardiology and Biophysics Division, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; <sup>f</sup>St. Vincent's Clinical School, University of New South Wales, Kensington, New South Wales, Australia; <sup>g</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; <sup>h</sup>INSERM, Paris Cardiovascular Research Center, Paris, France; <sup>i</sup>Faculty of Medicine, Paris-Descartes University, Sorbonne Paris Cité, Paris, France; and the <sup>j</sup>Department of Genetics, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. \*Drs. Adlam and Olson are co-first authors. The French SCAD study was supported by the

Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of unheralded acute myocardial infarction (AMI) (1,2). SCAD occurs predominantly in young to middle-aged women, accounting for 23% to 36% of AMI cases in this population (3-6), and is a rare cause of sudden cardiac death (7). SCAD also is the most common cause of pregnancy-associated AMI, although AMI in pregnant women accounts for only 2% to 18% of all SCAD cases (8,9). SCAD is caused by the development of an intimal tear and flap or an intramural hematoma in the outer third of the tunica media of the vessel wall, which leads to external compression of the true lumen and coronary insufficiency, myocardial ischemia, and infarction (10).

SEE PAGE 67

The causes of SCAD are poorly understood. Women with SCAD are typically not overweight and do not have many atherosclerotic risk factors. In observational studies, SCAD has been associated with a high prevalence of extracoronary arteriopathies, especially fibromuscular dysplasia (FMD) (1,2,11-16). FMD is a noninflammatory, non-atherosclerotic disease of medium size arteries, which may lead to complications arising from arterial stenosis, aneurysms, or dissections (17,18). FMD most commonly involves renal, carotid, and iliac arteries, but any arterial bed may be affected. The clinical overlap between SCAD and FMD includes a predilection for young to middle-aged women and a low prevalence of coexistent atherosclerotic disease (12,19-22).

Occasional familial cases of SCAD have been reported mainly in siblings or mother-daughter pairs (21). Hereditary connective tissue disorders appear rare, accounting for <5% of SCAD cases, and genetic screening for mutations in known connective tissue genes in SCAD survivors has a low yield (23,24), similar to genetic screening in FMD (25). The extent to which common genetic variants may affect susceptibility to SCAD is unknown.

*PHACTR1/EDN1* is a genetic locus on chromosome 6q24 reported to confer risk for coronary artery disease (CAD) and AMI (26,27). *PHACTR1/EDN1* is also associated with migraine (28) and cervicocerebral artery dissection (CeAD) (29). The putative causal genetic variant at the *PHACTR1* locus has recently been reported to lie in a putative enhancer region for *EDN1*, the endothelin (ET)-1 gene (30). The present authors recently showed that this variant is also associated with the risk of FMD (31). Interestingly, the common allele, rs9349379-A, is associated with an increased risk for FMD, migraine, and CeAD, whereas the minor allele, rs9349379-G, associates with increased risk for atherosclerotic CAD and AMI (32). The present study aimed to investigate the association between rs9349379 and SCAD, to assess whether, at this locus, SCAD is genetically closer to FMD, given their clinical overlap, or to atherosclerotic CAD and AMI.

## METHODS

**STUDY POPULATIONS.** Participants included in this study were predominantly from 4 different countries, all of European descent, which was determined by using ancestry markers and clinical records. The diagnosis of SCAD was confirmed by review of the index coronary angiogram by an experienced interventional cardiologist with expertise in the recognition of SCAD, along with contemporaneous medical records, following criteria described elsewhere (6,33). Individuals without a diagnostic angiogram were excluded from this analysis. Screening for FMD was undertaken in 491 SCAD patients from the Mayo Clinic study who underwent computed tomography angiography imaging of at least 2 arterial beds from brain to pelvis (14). Pregnancy-associated SCAD (P-SCAD) was defined as SCAD during pregnancy or occurring  $\leq 12$  weeks postpartum. Recurrent SCAD

## ABBREVIATIONS AND ACRONYMS

<b>AMI</b>	= acute myocardial infarction
<b>CAD</b>	= coronary artery disease
<b>CeAD</b>	= cervicocerebral artery dissection
<b>CI</b>	= confidence interval
<b>EDN1</b>	= endothelin gene
<b>ET</b>	= endothelin
<b>FMD</b>	= fibromuscular dysplasia
<b>OR</b>	= odds ratio
<b>PHACTR1</b>	= phosphatase and actin regulatory 1 gene
<b>P-SCAD</b>	= pregnancy-associated spontaneous coronary artery dissection
<b>R-SCAD</b>	= recurrent spontaneous coronary artery dissection
<b>SCAD</b>	= spontaneous coronary artery dissection

French Society of Cardiology foundation, *Coeur et recherche*, the French Coronary Atheroma and Interventional Cardiology Group, and European Research Council grant ERC-Stg-ROSALIND-716628 to Dr. Bouatia-Naji. The U.K. SCAD study was supported by the British Heart Foundation and National Institute for Health Research rare disease translational collaboration, the Leicester NIHR Biomedical Research Centre, and BeatSCAD. The Mount Sinai DEFINE-FMD study was supported by a philanthropic gift. The Australian study was supported by National Health and Medical Research Council of Australia grant 1074386, the Cardiac Society of Australia and New Zealand, St. Vincent's Clinic Foundation, the Catholic Archdiocese of Sydney, and SCAD Research Inc., Australia. The Mayo Clinic SCAD study was supported by SCAD Research, Inc., the Department of Cardiovascular Medicine, Mayo Clinic, and the National Institutes of Health "Building Interdisciplinary Research Careers in Women's Health" program grant NH HD 65987 to Dr. Tweet. Dr. Adlam has received research funding from Abbott Vascular Inc. and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received August 24, 2018; revised manuscript received September 21, 2018, accepted September 21, 2018.

**TABLE 1 Clinical Characteristics of Study Populations**

Cohorts	N	Females	Median Age at Inclusion, yrs (Q1-Q3)	Median Age at 1st Event, yrs (Q1-Q3)	P-SCAD	Recurrent SCAD	Study Recruitment
French cases	189	170 (90)	51 (44-59)	NA	NA	NA	National register
French controls (PPS3)	3,964	1,012 (40)	58.73 ± 5.94	NR	NR	NR	Population-based
U.K. cases	202	194 (96)	46 (42-53)	44 (38-50)	18 (9)	23 (11)	Mainland U.K. nationwide
U.K. controls (B58)	606	582 (96)	44 (44-44)	NR	NR	NR	Mainland U.K. nationwide
AU/Mount Sinai cases	160	154 (96)	50 (45-57)	46 (41-54)	14 (9)	18 (11)	Social media platform
AU/Mount Sinai controls	1,127	672 (60)	>75	NR	NR	NR	Healthy volunteers
Mayo Clinic cases	504	482 (96)	48 (41-55)	45 (39-53)	53 (11)	81 (16)	Mayo Clinic patients, physician referrals, and social media
Mayo Clinic controls	1,493	1,423 (95)	48 (41-55)	NR	NR	NR	Healthy volunteers (Mayo Genome Consortia)

Values are n, n (%), or mean ± SD unless otherwise indicated. Note, for the birth cohort B85, median Q1 and Q3 are equal to 44 yrs.  
AU = Australian study; NA = not available; NR = not relevant; PPS3 = Paris Prospective Study 3; P-SCAD = pregnancy spontaneous coronary artery dissection; Q1-Q3 = quartile 1-quartile 3; SCAD = spontaneous coronary artery dissection.

(R-SCAD) was considered when de novo SCAD was unrelated to the index dissection and affected different coronary artery segments. All participants provided written informed consent, and all individual studies were approved by national and institutional review boards. A detailed description of each study and the DISCO (Etude de la prévalence de la dysplasie fibromusculaire chez les patients présentant une DISsection Coronaire) Consortium and CARDIOGRAMPlusC4D (Coronary ARtery Disease Genome wide Replication and Meta-analysis (CARDIOGRAM) plus The Coronary Artery Disease [C4D] Genetics consortium) Study Group is provided in the [Online Appendix](#). Genotypes were generated from different platforms in each of the 4 studies, and the genotype distributions did not significantly deviate from Hardy-Weinberg equilibrium ([Online Table 1](#)).

To compare the associations of rs9349379 with SCAD and with CAD/AMI, sex-specific associations of rs9349379 were evaluated in the meta-analysis of a genome-wide association study dataset of CAD assembled by the CARDIOGRAMPlusC4D consortium. This dataset included 43,171 AMI cases and 127,176 controls, 9,105 women with CAD and 30,428 female controls, and 30,428 men with CAD and 36,042 male controls (26).

**STATISTICAL METHODS.** To estimate the association between rs9349379 and SCAD, genotype distributions were compared between cases and controls in 4 independent studies. Analyses were performed using R software versions 3.3.1 and 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria), PLINK version 1.07 or 1.9 software (Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts), SAS version 9.4 software (Cary, North Carolina), or Stata version 15.1 software

(StataCorp, College Station, Texas). Associations found using the additive genetic model were estimated using logistic regression adjusted for age and sex when relevant. In the U.K. study, controls were from a birth cohort and were all 44 years of age. Controls in the Mayo Clinic study were older and were matched for sex and ethnic group to cases.

To estimate the global effect on SCAD, a fixed effects inverse variance-weighted method was used, which combines the beta's (log-odds ratios) weighting by the inverse variance of the log-odds estimate, thereby accounting for study sample size.

The association with age at first SCAD occurrence was estimated by using linear (age continuous) or logistic (SCAD <40 years) regression. The genetic effect on P-SCAD under the additive model was only analyzed in women by using logistic regression analyses and time to R-SCAD using Cox proportional hazards regression. The meta-analyzed effect was estimated using the same method used for global association.

## RESULTS

**CLINICAL CHARACTERISTICS.** [Table 1](#) summarizes clinical characteristics of the 1,055 patients and 7,190 controls studied to estimate the association between rs9349379 and SCAD. Cases were recruited through diverse settings, including clinician referral to a national registry (French study), social media platforms, and a combination of both patient and physician referrals (United Kingdom, Mayo Clinic, and Australian/Mount Sinai studies), and showed overall similar clinical characteristics. SCAD patients were mostly women (87% to 96%) whose SCAD event occurred in middle age. P-SCAD or recurrence each occurred in approximately 10% of cases, as estimated from 3 of 4

cohorts where this information was available. In 491 SCAD patients in whom FMD screening was conducted, 45% (n = 206) showed at least 1 extracoronary artery was affected.

**ASSOCIATION OF rs9349379 WITH SCAD.** The rs9349379-A allele showed a higher prevalence among SCAD patients and its frequency was estimated to be 0.72 in the 1,100 patients studied compared to a frequency of 0.56 in the controls, and was significantly associated with increased risk for SCAD (Table 2). Under the additive model, the odds ratio (OR) per risk allele increment was estimated to be 1.67 (95% confidence interval [CI]: 1.50 to 1.86;  $p = 1.10 \times 10^{-21}$ ) in the combined meta-analysis (Table 2, Figure 1). Overall, the Cochran Q statistic did not show evidence for heterogeneity in the combined meta-analyses (Table 2). The stratified analysis for the presence of FMD was conducted in the Mayo Clinic case control study (Table 3). The OR estimate was found to be higher for the association of SCAD in patients without FMD (OR: 1.89; 95% CI: 1.53 to 2.33;  $p = 3.8 \times 10^{-9}$ ) than in SCAD cases with FMD (OR: 1.60; 95% CI: 1.28 to 1.99;  $p = 3.5 \times 10^{-5}$ ) (Table 3).

**ASSOCIATION OF rs9349379 WITH SCAD VERSUS CLASSICAL AMI AND CAD.** Figure 2 summarizes the association between rs9349379 and SCAD and compares the effect size estimates of CAD/AMI globally and stratified by sex. The direction of effect of the association of rs9349379-A allele with SCAD (OR: 1.67; 95% CI: 1.50 to 1.86;  $p = 6.76 \times 10^{-21}$ ) is identical to that of FMD (OR: 1.39; 95% CI: 1.25 to 1.54;  $p = 7.40 \times 10^{-10}$ ) but opposite to the more common atherosclerotic forms of AMI/CAD (OR: 0.88; 95% CI: 0.86 to 0.89;  $p = 1.81 \times 10^{-42}$ ), including when the analysis was restricted to women only (OR: 0.92; 95% CI: 0.88 to 0.96;  $p = 6.09 \times 10^{-5}$ ) (Figure 2, Central Illustration). The specific association of the *PHACTR1* locus alleles with FMD and SCAD, which are predominantly affecting women and CAD/AMI, which are predominantly affecting men, is summarized in the Central Illustration.

**PREVALENCE OF rs9349379 IN SCAD SUBGROUPS.** Among SCAD patients in whom data were available, 87 of 835 patients presented with P-SCAD, and 118 of 872 had documented R-SCAD. Differences in the risk allele distribution were not identified in P-SCAD, R-SCAD. SCAD risk allele did not influence age at first event (Online Table 2).

**ASSOCIATION WITH CIRCULATING ET-1.** ET-1 expression was measured in a subsample of U.K. SCAD patients with clinical characteristics that were similar to those of patients studied in the U.K. case control study (98% women; mean  $46.7 \pm 8.01$  years

**TABLE 2 Association Between rs9349379 and SCAD in 4 Case Control Studies**

Case Control Study	N	GG	GA	AA	EAF	OR*† (95% CI)	p Value*†
French cases	189	12	65	112	0.76		
French controls (PPS3)	3,964	574	1,795	1,595	0.63	1.81 (1.39-2.35)	$1.03 \times 10^{-5}$
U.K. cases	202	16	99	87	0.68		
U.K. controls (B58)	606	105	275	226	0.60	1.38 (1.09-1.75)	$7.00 \times 10^{-3}$
AU/Mount Sinai cases	160	12	70	78	0.71		
AU/Mount Sinai controls	1,127	187	536	404	0.60	1.66 (1.27-2.15)	$1.56 \times 10^{-4}$
Mayo Clinic cases	504	40	199	265	0.72		
Mayo Clinic controls	1,493	255	703	535	0.59	1.77 (1.51-2.07)	$1.00 \times 10^{-12}$
Total cases	1,055	80	433	542	0.72		
Total controls	7,190	1,121	3,309	2,760	0.61	1.67 (1.50-1.86)	$6.76 \times 10^{-21}$


\*OR and p values were computed using logistic regression under the additive genetic model. †Meta-analysis was performed using the inverse variance-weighted method. Heterogeneity among cohorts was tested using Cochran's Q statistic and was not significant (chi-square value: 3.38; *df* = 3;  $p = 0.337$ ).  
 CI = confidence interval; EAF = effect allele frequency; OR = odds ratio; other abbreviations as in Table 1.

of age). This analysis showed that, as in healthy subjects (30), there was an association between lower levels of ET-1 in plasma of patients and the presence of the rs9349379-A allele ( $p < 0.05$ ) (Online Figure 1, Online Methods).

## DISCUSSION

**FIRST GENETIC RISK VARIANT FOR SCAD IS PROTECTIVE AGAINST ATHEROSCLEROTIC MYOCARDIAL INFARCTION.** In this large genetic study conducted in >1,000 SCAD patients and ~7,200 controls, robust and replicated associations are reported between rs9349379, a common noncoding variant in the *PHACTR1/EDN1* locus, and the risk of SCAD. This is the first report showing that a genetic risk locus for SCAD is estimated to contribute to an increased risk of ~70% among carriers of the A allele, but the study did not partition age or the specific phenotypic subgroups, namely, R-SCAD and P-SCAD subjects.

**A GENETIC LINK BETWEEN SCAD AND FMD.** FMD has been reported to be highly prevalent in SCAD patients in multiple observational studies (1,2,11-16). A recent case report described evidence for histological FMD in the coronary event of a patient who died from SCAD (34). The finding of an association between rs9349379 and SCAD risk provides a molecular rationale for this clinical observation, given that rs9349379 has also recently been established as a risk variant for FMD (31). Compared to the prevalence of FMD, the prevalence of the risk allele seems to be higher among SCAD patients (frequency in FMD [FreqFMD]: 0.69 vs. 0.72 for frequency in SCAD [FreqSCAD];  $p$  for trend = 0.06), with slightly overlapping estimation of risk for both diseases (OR for



FMD [ORFMD]: 95% CI: 1.25 to 1.54 vs. OR for SCAD [ORSCAD]: 95% CI: 1.50 to 1.86 (**Central Illustration, Figure 2**). This observation is supported by the bigger effect size estimated for the association of rs9349379 with SCAD without FMD, which also mitigates concerns for variable completeness of extracoronary arterial bed screening and the potential admixture of subtle or undetected FMD in the subgroup “SCAD without FMD.” However, sample sizes in both FMD and SCAD analyses were relatively modest, and larger and clinically more diverse cohorts with systematic assessments of SCAD and FMD in the same patients will be required to confirm this trend for a higher prevalence of the rs9349379-A allele in SCAD than in FMD. These findings, however, do support the hypothesis that SCAD, like FMD, may be a complex genetic disease involving multiple genetic risk factors, each exerting a moderate effect in response to environmental triggers.

**SCAD AND ATHEROSCLEROTIC CAD/AMI.** Observational studies in SCAD have noted a low frequency of coincidental atherosclerotic CAD (3,6,20,22,33). Interestingly, rs9349379 is also a well-established risk locus for CAD and myocardial infarction (MI) (27). The

association between the protective allele for CAD/AMI with SCAD provides a genetic explanation for this observation, given that the allele that increases the risk of SCAD is identical in FMD but opposite to the risk allele for CAD and MI, both in the overall SCAD cohort and in the group consisting of women only (**Figure 2, Central Illustration**) (27).

**A GENETIC LINK BETWEEN SCAD AND SEVERAL NEUROVASCULAR DISEASES.** In addition to providing an explanation for the clinical association between SCAD and FMD, rs9349379 also links SCAD with both CeAD, a rare condition defined as an intimal flap or intramural hematoma in a carotid or vertebral artery that can cause stroke (29) and migraine (28). Importantly, rs9349379-A is a reported risk allele for both of these disorders. A higher prevalence of migraine has been consistently described in observational studies of SCAD patients, ranging from 33% to 43%, than in a population prevalence of ~15% (35-37). Although the population incidence of CeAD is rare, there are multiple series describing CeAD in SCAD patients either preceding the SCAD event or discovered during follow-up imaging, usually in association with cervical FMD (11,16,38). However, further global genetic investigation is required, using full genome-wide association studies in both SCAD and FMD patients to assess the extent to which CeAD shares genetic susceptibility with these diseases.

**POTENTIAL REGULATORY MECHANISMS OF rs9349379.** Involvement of the same genetic variant in a diverse panel of cardiovascular and neurovascular diseases is intriguing, and the underlying mechanisms remain to be fully elucidated. Initial molecular investigation at this locus was focused on

**TABLE 3 Association Analysis Stratified by the Presence of FMD in Mayo Clinic SCAD Patients**

	N	GG	GA	AA	EAF	OR* (95% CI)	p Value*
All SCAD cases	504	40	199	265	0.72	1.77 (1.51-2.07)	$1.00 \times 10^{-12}$
SCAD with FMD	206	25	72	109	0.70	1.60 (1.28-1.99)	$3.18 \times 10^{-5}$
SCAD without FMD	253	13	108	132	0.73	1.89 (1.53-2.33)	$3.83 \times 10^{-9}$
Mayo Clinic controls	1,493	255	703	535	0.59		

\*Odds ratios and p values were computed by using logistic regression under the additive genetic model. FMD = fibromuscular dysplasia; other abbreviations as in Tables 1 and 2.




**FIGURE 2** Associations Between rs9349379 and SCAD Were Compared With the Associations Previously Reported Between FMD and CAD/AMI Globally and Those Stratified by Sex

Disease	Case/Control		OR (95% CI)	EAF	P Value	Study
SCAD	1,055/7,190		1.67 (1.50-1.86)	0.63	$6.76 \times 10^{-21}$	Current Study
FMD	1,154/3,895		1.39 (1.25-1.54)	0.63	$7.40 \times 10^{-10}$	Kiando et al. 2016
MI	43,171/127,176		0.88 (0.86-0.89)	0.59	$1.81 \times 10^{-42}$	Nikpay et al. 2015
Women CAD	9,105/30,428		0.92 (0.88-0.96)	0.57	$6.09 \times 10^{-5}$	Nikpay et al. 2015
Men CAD	30,428/36,042		0.89 (0.86-0.91)	0.56	$1.83 \times 10^{-19}$	Nikpay et al. 2015

The effecting allele is the A allele for all diseases analyzed, which is the risk allele for SCAD and FMD, but which is protective for CAD/AMI. The association is the opposite between SCAD and CAD/MI, including in the analysis of female control cases. CAD/AMI = coronary artery disease/acute myocardial infarction; CI = confidence interval; EAF = effect allele frequency; FMD = fibromuscular dysplasia; OR = odds ratio; SCAD = spontaneous coronary artery dissection.

**CENTRAL ILLUSTRATION** Genetic Variant rs9349379 Associates With Spontaneous Coronary Artery Dissection



Adlam, D. et al. *J Am Coll Cardiol.* 2019;73(1):58-66.

Summary of the genetic associations between the *PHACTR1* locus represented by the common variant rs9349379 that associates with the genetic risk of FMD, SCAD, CAD, and MI. Our study provides evidence supporting an increased risk for FMD and SCAD among patients carrying the rs9349379-A allele. This association is the first step toward establishing a molecular mechanism for the clinical associations observed between SCAD and FMD. FMD and SCAD are predominantly affecting women who represent up to 90% of patients. The rs9349379-G allele on the other hand, has been reported to increase the risk of CAD and more classical MI, where most of patients are men. CAD/MI = coronary artery disease/myocardial infarction; EAF = effect allele frequency; FMD = fibromuscular dysplasia; SCAD = spontaneous coronary artery dissection.

the closest gene that encodes PHACTR1, a phosphatase and actin regulator protein suggested to be involved in angiogenesis and cell migration (39). The rs9349379 allele is an expression quantitative locus for *PHACTR1* in skin fibroblasts (31), macrophages (40), and many arterial tissues, available in the GTEx catalog (Genotype-Tissue Expression [GTEx] Program, National Institutes of Health, Bethesda, Maryland) (41). Another study showed that the rs9349379-G allele disrupts a binding site for the myocyte enhancer factor 2 (MEF2) protein, but that study did not find the previously claimed regulation by VEGF (42). Gupta et al. (30) recently used genome editing of pluripotent stem cells to show that the rs9349379-G allele correlates with increased expression of ET-1, but not PHACTR1, during the differentiation to endothelial and smooth muscle lineages. This study suggests the ET-1 gene (*EDN1*), which maps ~600 kbp upstream of artery-specific enhancers, may mediate several important biological mechanisms for vascular diseases genetically linked to rs9349379 (e.g., vasoconstriction, proliferation, and vasodilation) (30). In addition, in the study by Gupta et al. (30), the rs9349379-A allele was reported to associate with lower levels of circulating ET-1 in healthy volunteers, which the present authors also found to be the case in SCAD patients. The well-known hemodynamic and vascular effects of ET-1 provide an attractive potential contributing mechanism for many of the vascular diseases where rs9349379 is genetically involved. However, whether ET-1 expression is decreased in SCAD, FMD, or CeAD compared to that in healthy individuals is not known. The present lack of evidence for significant hemodynamic differences in SCAD populations suggests that the effect on ET-1 would be insufficient to explain the large spectrum of clinical manifestations associated with this locus. ET-1 biological actions are diverse and compensatory through its receptors ET<sub>A</sub> and ET<sub>B</sub>, which mediate opposing vasoconstrictor and vasodilator effects, although human coronary arteries only express the ET<sub>A</sub> subtype (43). Further investigation is needed to confirm whether reduced ET-1 levels may result in increased risks for SCAD, FMD, and CeAD. In addition, the possible contributions and roles of other coding and noncoding genes at this locus, including *PHACTR1*, cannot be ruled out at this stage, especially in the complex genetic context contributing to these vascular disorders, which includes multiple genetic and environmental triggering factors.

**STUDY LIMITATIONS.** This study is a cross-sectional case control design of a single genetic locus. Thus, the

finding reported only represents one of the many of the genetic risk determinants for SCAD where we observe a positively shared genetic association between SCAD and FMD, which is opposite between SCAD and atherosclerotic CAD in women. Also, we have combined data from different national studies using different methodologies, and we still have applied unified diagnostic criteria for selection of patients and controls. Another limitation of our study is the relatively modest samples included in the stratified analyses for P-SCAD, R-SCAD and SCAD without FMD, which may have biased the current findings.

## CONCLUSIONS

This study reports that rs9349379 is the first genetic risk locus for SCAD. The previously reported association between this common variant and other vascular disorders, especially FMD, provides a genetic explanation for the established clinical associations among these disorders. Further studies will be required to confirm the relative importance of the endothelin mechanistic pathway and its relevance to SCAD and FMD risks.

**ACKNOWLEDGMENTS** The authors thank our clinical colleagues throughout Europe, Australia, and the United States who referred SCAD cases to our research studies, and our patients who supported this research. The authors also thank all clinicians who contributed to the DISCO (Etude de la prévalence de la dysplasie fibromusculaire chez les patients présentant une DISsection Coronaire) register. The U.K. SCAD study specifically acknowledges Ellie Clarke, Jenny Middleton, Martin Batty, Emma Beeston, and Tara Maitland for their support of SCAD research. The authors acknowledge the leadership of the ESC-ACCA (European Society of Cardiology-Acute Cardiovascular Care Association) SCAD study group and the support of SCAD survivors. The Australian SCAD study specifically acknowledges support from Pamela McKenzie and Sarah Ford, President, SCAD Research Inc., Australia.

**ADDRESSES FOR CORRESPONDENCE:** Dr. Nabila Bouatia-Naji, Paris Cardiovascular Research Center, INSERM UMR970, 56 Rue Leblanc, F-75015, Paris, France. E-mail: [nabila.bouatia-naji@inserm.fr](mailto:nabila.bouatia-naji@inserm.fr). Twitter: [@n\\_bouatianaji](https://twitter.com/n_bouatianaji), [@Inserm](https://twitter.com/Inserm), [@parcc\\_inserm](https://twitter.com/parcc_inserm). OR Dr. David Adlam, Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Unit, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, United Kingdom. E-mail: [da134@le.ac.uk](mailto:da134@le.ac.uk). Twitter: [@LeicesterBRC](https://twitter.com/LeicesterBRC).

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** Identification of a risk locus suggests that SCAD may be genetically determined with a complex pattern of inheritance. Genetic susceptibility to SCAD through the *PHACTR1/EDN1* locus is shared with FMD.

**TRANSLATIONAL OUTLOOK:** Further research is necessary to establish the molecular mechanisms responsible for the clinically observed associations between SCAD and FMD.

## REFERENCES

1. Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation* 2018;137:e523-57.
2. Adlam D, Alfonso F, Maas A, Vrints C, Writing Committee. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J* 2018;39:3353-68.
3. Motreff P, Malcles G, Combaret N, et al. How and when to suspect spontaneous coronary artery dissection: novel insights from a single-centre series on prevalence and angiographic appearance. *EuroIntervention* 2017;12:e2236-43.
4. Nakashima T, Noguchi T, Haruta S, et al. Prognostic impact of spontaneous coronary artery dissection in young female patients with acute myocardial infarction: a report from the angina pectoris-myocardial infarction multicenter investigators in Japan. *Int J Cardiol* 2016;207:341-8.
5. Rashid HN, Wong DT, Wijesekera H, et al. Incidence and characterisation of spontaneous coronary artery dissection as a cause of acute coronary syndrome—a single-centre Australian experience. *Int J Cardiol* 2016;202:336-8.
6. Saw J, Aymong E, Mancini GB, Sedlak T, Starovoytov A, Ricci D. Nonatherosclerotic coronary artery disease in young women. *Can J Cardiol* 2014;30:814-9.
7. Desai S, Sheppard MN. Sudden cardiac death: look closely at the coronaries for spontaneous dissection which can be missed. A study of 9 cases. *Am J Forensic Med Pathol* 2012;33:26-9.
8. Faden MS, Bottega N, Benjamin A, Brown RN. A nationwide evaluation of spontaneous coronary artery dissection in pregnancy and the puerperium. *Heart* 2016;102:1974-9.
9. Elkayam U, Jalnarpurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. *Circulation* 2014;129:1695-702.
10. Al-Hussaini A, Adlam D. Spontaneous coronary artery dissection. *Heart* 2017;103:1043-51.
11. Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. *Circulation* 2012;126:579-88.
12. Toggweiler S, Puck M, Thalhammer C, et al. Associated vascular lesions in patients with spontaneous coronary artery dissection. *Swiss Med Wkly* 2012;142:w13538.
13. Saw J, Poulter R, Fung A, Wood D, Hamburger J, Buller CE. Spontaneous coronary artery dissection in patients with fibromuscular dysplasia: a case series. *Circ Cardiovasc Interv* 2012;5:134-7.
14. Prasad M, Tweet MS, Hayes SN, et al. Prevalence of extracoronary vascular abnormalities and fibromuscular dysplasia in patients with spontaneous coronary artery dissection. *Am J Cardiol* 2015;115:1672-7.
15. Persu A, Van der Niepen P, Touze E, et al. Revisiting fibromuscular dysplasia: rationale of the European fibromuscular dysplasia initiative. *Hypertension* 2016;68:832-9.
16. Liang JJ, Prasad M, Tweet MS, et al. A novel application of CT angiography to detect extracoronary vascular abnormalities in patients with spontaneous coronary artery dissection. *J Cardiovasc Comput Tomogr* 2014;8:189-97.
17. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. *Circulation* 2014;129:1048-78.
18. Persu A, Giavarini A, Touze E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. *J Hypertens* 2014;32:1367-78.
19. Michelis KC, Olin JW, Kadian-Dodov D, d'Escamard V, Kovacic JC. Coronary artery manifestations of fibromuscular dysplasia. *J Am Coll Cardiol* 2014;64:1033-46.
20. Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. registry for FMD. *J Am Coll Cardiol* 2016;68:176-85.
21. Goel K, Tweet M, Olson TM, Maleszewski JJ, Gulati R, Hayes SN. Familial spontaneous coronary artery dissection: evidence for genetic susceptibility. *JAMA Intern Med* 2015;175:821-6.
22. Tweet MS, Akhtar NJ, Hayes SN, Best PJ, Gulati R, Araoz PA. Spontaneous coronary artery dissection: Acute findings on coronary computed tomography angiography. *Eur Heart J Acute Cardiovasc Care* 2018. 2048872617753799.
23. Henkin S, Negrotto SM, Tweet MS, et al. Spontaneous coronary artery dissection and its association with heritable connective tissue disorders. *Heart* 2016;102:876-81.
24. Kaadan MI, MacDonald C, Ponzini F, et al. Prospective cardiovascular genetics evaluation in spontaneous coronary artery dissection. *Circ Genom Precis Med* 2018;11:e001933.
25. Poloskey SL, Kim E, Sanghani R, et al. Low yield of genetic testing for known vascular connective tissue disorders in patients with fibromuscular dysplasia. *Vasc Med* 2012;17:371-8.
26. Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 2009;41:334-41.
27. Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 2015;47:1121-30.
28. Anttila V, Winsvold BS, Gormley P, et al. Genome-wide meta-analysis identifies new susceptibility loci for migraine. *Nat Genet* 2013;45:912-7.
29. DeBette S, Kamatani Y, Metso TM, et al. Common variation in *PHACTR1* is associated with susceptibility to cervical artery dissection. *Nat Genet* 2015;47:78-83.
30. Gupta RM, Hadaya J, Trehan A, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. *Cell* 2017;170:522-33.
31. Kiando SR, Tucker NR, Castro-Vega LJ, et al. *PHACTR1* is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance. *PLoS Genet* 2016;12:e1006367.



32. Consortium CAD, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet* 2013;45:25-33.
33. Tweet MS, Eleid MF, Best PJ, et al. Spontaneous coronary artery dissection: revascularization versus conservative therapy. *Circ Cardiovasc Interv* 2014;7:777-86.
34. Moulson N, Kelly J, Iqbal MB, Saw J. Histopathology of coronary fibromuscular dysplasia causing spontaneous coronary artery dissection. *J Am Coll Cardiol Interv* 2018;11:909-10.
35. Saw J, Ricci D, Starovoytov A, Fox R, Buller CE. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. *J Am Coll Cardiol Interv* 2013;6:44-52.
36. Saw J, Humphries K, Aymong E, et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. *J Am Coll Cardiol* 2017;70:1148-58.
37. Eleid MF, Guddeti RR, Tweet MS, et al. Coronary artery tortuosity in spontaneous coronary artery dissection: angiographic characteristics and clinical implications. *Circ Cardiovasc Interv* 2014;7:656-62.
38. McGrath-Cadell L, McKenzie P, Emmanuel S, Muller DW, Graham RM, Holloway CJ. Outcomes of patients with spontaneous coronary artery dissection. *Open Heart* 2016;3:e000491.
39. Allain B, Jarray R, Borriello L, et al. Neuropilin-1 regulates a new VEGF-induced gene, Phactr-1, which controls tubulogenesis and modulates lamellipodial dynamics in human endothelial cells. *Cell Signal* 2012;24:214-23.
40. Reschen ME, Lin D, Chalisey A, Soilleux EJ, O'Callaghan CA. Genetic and environmental risk factors for atherosclerosis regulate transcription of phosphatase and actin regulating gene PHACTR1. *Atherosclerosis* 2016;250:95-105.
41. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580-5.
42. Beaudoin M, Gupta RM, Won HH, et al. Myocardial infarction-associated SNP at 6p24 interferes with MEF2 binding and associates with PHACTR1 expression levels in human coronary arteries. *Arterioscler Thromb Vasc Biol* 2015;35:1472-9.
43. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. *Pharmacol Rev* 2016;68:357-418.

---

**KEY WORDS** cardiovascular disease in women, fibromuscular dysplasia, genetic association, myocardial infarction

---

**APPENDIX** For expanded methods, supplemental figures and tables, and a complete list of the DISCO Consortium and CARDIoGRAMPlusC4D Study Group members, please see the online version of this paper.